John Petrie is Professor of Diabetes at the University of Glasgow and Director of the Robertson Centre for Biostatistics and Clinical Trials Unit. He graduated from Edinburgh University medical school and did his early clinical training in Glasgow, followed by a PhD on insulin sensitivity and endothelial function. He completed further clinical and postdoctoral training at the University of Glasgow. He was Reader in Diabetic Medicine at the University of Dundee from 2003, where he led the establishment of the Scottish Diabetes Research Network (SDRN).

His research aims to achieve a better understanding of vascular disease in types 1 and 2 diabetes, to improve treatments and prevent complications. It includes clinical investigation, cohort studies, biomarker discovery and clinical trials. From a background in clinical physiology and biochemistry (insulin assays, euglycaemic clamps, forearm plethysmography), his work has developed into leading academic and pharma-sponsored clinical trials and exploiting well-phenotyped cohorts for biomarker discovery and validation.

Professor Petrie has served on clinical trial committees for a number of pharmaceutical companies and contract research organisations, including Boehringer Ingelheim, Novo Nordisk, IQVIA, Roche and Sanofi.

His research has been supported financially by the Juvenile Diabetes Research Foundation, the Chief Scientist Office in Scotland, NIHR, the British Heart Foundation, Diabetes UK, European Union and industry partners.

He has made significant contributions to national and international guidelines for health professionals. For example, as a member of the joint American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) Technology Committee, he was lead author in 2015 of a statement on the risks and benefits of insulin pumps.

Professor Petrie was Associate Editor of the journal of the EASD, Diabetologia, until joining its Advisory Board in 2014. He is currently a Senior Associate Editor of the journal Cardiovascular Endocrinology.

He previously chaired the Board of Trustees of the Novo Nordisk UK Research Foundation and has served on many grant-awarding panels:  including the UK National Institute for Healthcare Research (NIHR),  the US National Institutes of Health (NIH), the US Juvenile Diabetes Research Foundation (JDRF), the National Health and Medical Research Council of Australia (NHMRC), the European Foundation for the Study of Diabetes (EFSD), the Academy of Finland, Danish Diabetes Academy, Diabetes UK and the Health Research Boards of Ireland.

Duality of interest: none declared

Date: Winter 2023